The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss before noncontrolling interest | -35,843 | -74,917 |
| Depreciation and amortization | 1,673 | 3,065 |
| Equity-based compensation | 6,676 | 12,957 |
| Gain on marketable securities, net | 732 | 1,942 |
| Gain on lease disposition | 0 | -143 |
| Impairment of long-lived assets | 318 | - |
| Loss on disposal of equipment | -10 | -464 |
| Interest receivable | -538 | -672 |
| Prepaid and other assets | -593 | -7,202 |
| Accounts payable and accrued expenses | 51 | -8,126 |
| Income taxes payable | 120 | -526 |
| Net cash flows used in operating activities | -26,596 | -61,008 |
| Purchases of marketable securities | 78,538 | 98,138 |
| Sales and maturities of marketable securities | 112,753 | 149,239 |
| Purchase of equipment and facility expansion | 5,197 | 4,247 |
| Net cash flows provided by investing activities | 29,018 | 46,854 |
| Proceeds from sales of class a ordinary shares, net of offering costs | 7,102 | 0 |
| Payments on finance leases | -5 | 26 |
| Exercise of stock options | 854 | - |
| Net cash flows (used in) provided by financing activities | 7,961 | -26 |
| Net change in cash and cash equivalents | 10,383 | -14,180 |
| Cash and cash equivalents at beginning of period | 99,120 | - |
| Cash and cash equivalents at end of period | 95,323 | - |
PROKIDNEY CORP. (PROK)
PROKIDNEY CORP. (PROK)